For instance, a study introduced the BRACE marker, derived from AI-based assessment of tumor heterogeneity in H&E images, which effectively stratified early-stage luminal/HER2-negative BC patients for distant metastasis-free survival and BC-specific survival, showing comparable prediction accuracy to traditional prognostic indices (132). This evidence concerns the gene ERBB2 and breast cancer.